review of the clinical evidence for interferon β 1a (rebif®) in the treatment of multiple sclerosis
Clicks: 167
ID: 153133
2008
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
167 views
23 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #74 of 117 articles by views in journal of crystal growth
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Francesco Manfredonia1, Livia Pasquali1, Angela Dardano2, Alfonso Iudice1, Luigi Murri1, Fabio Monzani21Department of Neuroscience and 2Department of Internal Medicine, University of Pisa, Pisa, ItalyAbstract: Interferon (INF) β 1a 22 or 44 µg (Rebif®) administered s.c. 3 times a week (t.i.w) is a well established immunomodulating treatment for relapsing remitting multiple sclerosis (RRMS). This review focuses on its mechanisms of action, evidence of efficacy, safety, and tolerability. Several pharmacodynamic properties explain the immunomodulatory actions of INF β 1a 22 or 44 µg s.c. t.i.w. Pivotal trials and post-marketing studies proved that the drug is effective in reducing disease activity and likely in slowing disease progression. Head-to-head comparative studies with other marketed INFs β in RRMS suggested a better therapeutic response associated with higher doses and frequency of administration of Rebif®. Additional evidence indicated a beneficial effect of INF β 1a in patients with clinically isolated syndromes (CIS) suggestive of MS, as treatment reduced time to conversion to clinically definite (CD) disease. Further, although the drug did not prove to slow time to progression there were benefits on relapse- and MRI-related secondary outcome measures in secondary progressive (SP) MS. Pivotal trials, their cross-over extensions, and post-marketing studies consistently showed that INF β 1a 22 or 44 µg s.c. t.i.w. is safe and well tolerated, as adverse drug reactions are usually mild and manageable.Keywords: interferon β 1a, multiple sclerosis, review, clinical trials, post-marketing studies
| Reference Key |
manfredonia2008neuropsychiatricreview
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Francesco Manfredonia;Livia Pasquali;Angela Dardano;Alfonso Iudice;Luigi Murri;Fabio Monzani |
| Journal | journal of crystal growth |
| Year | 2008 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.